News and Announcements
Leaf Resources September Update 2016
- Published November 01, 2016 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
31st October 2016, ASX Announcement
Highlights:
- Game changing period for Leaf as it signs JV agreement with leading USbased chemical project developer Claeris, LLC.
- Company well-funded to achieve next set of commercial milestones as its cash holding is bolstered by the successful completion of a $2.35m capital raise.
- Significant milestones achieved post September quarter with strong pipeline of potential announcements in the near term.
Leaf Resources (ASX: LER, “Leaf” or the “Company”) is pleased to provide the following update on its activities for the three months ended 30th September 2016. The Company reached an inflection point in the commercialisation of its proprietary GlycellTM technology in the past few months.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
